{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:07Z","timestamp":1790351467766,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01642-6","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T18:59:15Z","timestamp":1734548355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct03578367","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Timothy P.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elza","family":"Lomaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becki","family":"Nieman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Quenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"5","key":"1642_CR1","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186\u201393.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1642_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"1","key":"1642_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2024;22(1):43\u201369.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"23","key":"1642_CR4","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"S Branford","year":"2007","unstructured":"Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13(23):7080\u20135.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1642_CR5","first-page":"162","volume":"91","author":"M Colombat","year":"2006","unstructured":"Colombat M, Fort MP, Chollet C, Marit G, Roche C, Preudhomme C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica. 2006;91(2):162\u20138.","journal-title":"Haematologica"},{"issue":"3","key":"1642_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ajh.25342","volume":"94","author":"J Cortes","year":"2019","unstructured":"Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346\u201357.","journal-title":"Am J Hematol"},{"issue":"7","key":"1642_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825\u201333.","journal-title":"Leukemia"},{"issue":"20","key":"1642_CR8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1642_CR9","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044\u201354.","journal-title":"Leukemia"},{"issue":"2","key":"1642_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440\u201353.","journal-title":"Leukemia"},{"key":"1642_CR11","unstructured":"Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation; 2023."},{"key":"1642_CR12","unstructured":"Novartis Europharm Limited. Scemblix (asciminib) [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Limited. 2024."},{"issue":"24","key":"1642_CR13","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315\u201326.","journal-title":"N Engl J Med"},{"issue":"5","key":"1642_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim D-W, Rea D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37(5):1048\u201359.","journal-title":"Leukemia"},{"key":"1642_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458.","journal-title":"Leuk Res"},{"issue":"21","key":"1642_CR16","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031\u201341.","journal-title":"Blood"},{"issue":"7647","key":"1642_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature"},{"issue":"3","key":"1642_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617\u201326.","journal-title":"Leukemia"},{"issue":"10","key":"1642_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398.","journal-title":"N Engl J Med"},{"key":"1642_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/01.HS9.0000845700.84142.c0","volume":"6","author":"T Hughes","year":"2022","unstructured":"Hughes T, Cortes JE, R\u00e9a D, Mauro MJ, Hochhaus A, Kim D-W, et al. P704: Asciminib provides durable molecular responses in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial. HemaSphere. 2022;6:599\u2013600.","journal-title":"HemaSphere"},{"issue":"S1","key":"1642_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/01.HS9.0000561812.22500.d8","volume":"3","author":"J Cortes","year":"2019","unstructured":"Cortes J, Lang F, Kim D-W, R\u00e9a D, Mauro MJ, Minami H, et al. Combination therapy using asciminib plus imatinib (IMA) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. HemaSphere. 2019;3(S1):397.","journal-title":"HemaSphere"},{"issue":"5","key":"1642_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32(5):415\u201323.","journal-title":"J Clin Oncol"},{"key":"1642_CR23","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2147\/CMAR.S177566","volume":"10","author":"KK Chen","year":"2018","unstructured":"Chen KK, Du TF, Wu KS, Yang W. First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Manag Res. 2018;10:3891\u2013910.","journal-title":"Cancer Manag Res"},{"key":"1642_CR24","unstructured":"ClinicalTrials.gov. Accessed March 19, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05384587."},{"key":"1642_CR25","unstructured":"ClinicalTrials.gov. Accessed March 19, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05456191."},{"key":"1642_CR26","unstructured":"ClinicalTrials.gov. Accessed March 19, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04971226."}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01642-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T19:03:24Z","timestamp":1734548604000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01642-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01642-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the sites' institutional review boards and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; no individual patient data are included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TPH received research funding from Novartis, and Bristol Myers Squibb, and consultancy fees from Novartis, Takeda, Terns Pharmaceuticals, Enliven Therapeutics, and Ascentage Pharma. JG has received payment for consultancy from Novartis and Incyte. He is a committee member of the European Hematologic Association. He reports grants to his patient advocacy organization from Novartis, Pfizer, Bristol Myers Squibb, Incyte, Takeda, and Terns Pharmaceuticals. D-WK received research funding from Novartis, Bristol Myers Squibb, Enliven, Korea Otsuka, Il-Yang, and PharmaEssentia; honoraria from Novartis, Bristol Myers Squibb, Enliven, Krea Otsuka, and Il-Yang; and speaker bureau fees from Novartis, Bristol Myers Squibb, Korea Otsuka, and Il-Yang. EL received personal fees from Novartis, and Pfizer and is a member of speakers bureaus for Novartis, Pfizer, and Fusion Pharma. JM received research funding from BeiGene. AT received personal fees from Novartis, Pfizer, and R-Pharma and is a member of the speakers bureaus for Novartis, Pfizer, and R-Pharma. JEC received research funding from AbbVie, Ascentage Pharma, Novartis, and Sun Pharma and consultancy fees from Lilly, Nerviano, Novartis, Pfizer, Rigel, Sun Pharma, Syndax, and Biopath Holdings. He holds stock options in and is a board member of Biopath Holdings. BN, and SQ are employees of Novartis. APC and SK are employees and shareholders of Novartis stock. GS declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}